Cendakimab (anti–IL-13) administration improves esophageal gene expression in eosinophilic esophagitis

2025/10/09 by Julie M. Caldwell, Adina Y. Ballaban, Adina Ballaban +6 · 1 voice · 1 citation
Immunology and Microbiology · Medicine · #Eosinophilic Esophagitis #Food Allergy and Anaphylaxis Research #IL-33, ST2, and ILC Pathways

paper · doi:10.1016/j.jaci.2025.08.032

openalex publication_date 2025/10/09 · crossref created 2025/10/09 · openalex created_date 2025/10/10 · crossref issued 2026/01/01 · crossref published 2026/01/01 · crossref published-print 2026/01/01 · crossref deposited 2026/06/05 · crossref indexed 2026/06/22 · openalex updated_date 2026/06/22

Citations

• Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Cited by

• IL-13 and calpain-14 suppress the expression of SPINK7 by regulating OVOL1 in eosinophilic esophagitis

Discussions

• Cendakimab (anti-IL-13) administration improves esophageal gene expression in eosinophilic esophagitis doi.org/10.1016/j.ja... [bsky, 1 points, 1 comments]